SOUTH SAN FRANCISCO, Calif., July 21 /PRNewswire-FirstCall/ -- Renovis, Inc. will webcast its second quarter 2006 conference call with the financial community beginning at 4:30 p.m. EDT on Thursday, July 27, 2006.
A news release discussing Renovis’ second quarter 2006 financial results will be issued Thursday, July 27, 2006, after the market closes at 4 p.m. EDT.
Interested parties may access the call by dialing 1-866-356-3095 in the United States and 1-617-597-5391 internationally. The participant code is 83762470. This call is being webcast by CCBN and can be accessed in the Investor Relations section of Renovis’ Web site at http://www.renovis.com . A replay of the Webcast will be available until August 3, 2006.
The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at http://www.fulldisclosure.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (http://www.streetevents.com ).
About Renovis
Renovis is a biopharmaceutical company primarily focused on the discovery and development of drugs for neurological diseases and disorders in areas of unmet medical need. Our most advanced product candidate, NXY-059, is in Phase III clinical trials for acute ischemic stroke with our exclusive licensee, AstraZeneca AB. NXY-059 has a proposed mechanism of action of free radical trapping. It is being studied as a neuroprotectant in clinical trials based on effects seen in experimental models of acute ischemic stroke. In addition to proprietary research programs in the areas of cytoprotection, pain and inflammation, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule VR1 antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury.
For additional information about the company, please visit http://www.renovis.com .
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Renovis cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward- looking statements that we make are described in greater detail in the “Risk Factors” section of our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 9, 2006, and our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 14, 2006. We do not assume any obligation to update any forward-looking statements.
INVESTORS: MEDIA: Renovis, Inc. Noonan Russo John C. Doyle David Schull (650) 266-1407 (858) 546-4810 doyle@renovis.comdavid.schull@eurorscg.com
Renovis, Inc.
CONTACT: Investors - John C. Doyle of Renovis, Inc., +1-650-266-1407,doyle@renovis.com; or Media - David Schull of Noonan Russo,+1-858-546-4810, david.schull@eurorscg.com, for Renovis
